摘要
目的探讨子宫内膜异位症保守性手术后应用不同药物辅助治疗的疗效及安全性。方法将80例经腹腔镜确诊并行保守性手术的子宫内膜异位患者随机分为两组,达菲林组30例,米非司酮组50例。术后分别使用达菲林和米非司酮,疗程均为6个月。将痛经症状、术后复发和停药后妊娠率作为临床疗效指标;阴道异常出血、体重增加和肝功损害作为评价副反应的指标,比较两者的临床疗效及不良反应情况。结果由于费用原因更换药物者4例,达菲林组最后入组26例。两组临床疗效的各项指标差异无统计学意义。达菲林组阴道异常出血率(3.8%)低于米非司酮组(22.4%),差异有统计学意义(P<0.05);两组体重增加及肝功损害率差异无统计学意义。结论子宫内膜异位症术后使用达菲林及米非司酮疗效无明显差异;达菲林安全性更高但由于费用昂贵限制其临床推广;综合各方面因素,米非司酮为更加理想的术后辅助用药。
Objective To investigate the efficacy and safety of the adjuvant treatment with different drugs after conservative endometriosis surgery. Methods Eighty patients diagnosed with endometriosis by Iaparoscopy and receiving conservative surgery were randomly divided into the diphere!ine group with 30 patients and the mifepristone group with 50 patients.The two groups were given diphereline and mifeprstone respectively for 6 months.The dysmenorrhea symptoms,postoperative recurrence and pregnancy rate after drug withdrawal were taken as the clinical efficacy indicators;The abnormal vaginal bleeding,weight gain and liver damage were taken as the evaluation indicators of side effects;The clinical efficacy and adverse reactions of the two groups were compared. Results Four patients of the diphereline group withdrew from the study due to the expenses,so 26 patients were inciuded into the diphereline group.The two groups had no statistically significant difference in each clinical efficacy indicators.The diphereline group（3.8%） was lower than the mifepristone group（22.4%）in the abnormal vaginal bleeding rate,with statistically significant difference（P 〈0.05）;The two groups had no statistically significant difference in the weight gain and the liver damage rate. Conclusion Diphereline and mifepristone have no significant difference in the efficacy after endometriosis surgery.Diphereline shows higher safety,but its high expense restricts its clinical promotion.Taking all factors into consideration,mifepristone is a more ideal postoperative adjuvant drugl
出处
《中国医药科学》
2013年第1期175-176,共2页
China Medicine And Pharmacy
